A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity

Pharmaceuticals

Vassilis Zoumpourlis¹  Nikolas Khoury¹  Michael Zachariadis²  Dimitris Tsiourvas³  Zili Sideratou³  Katerina N. Panagiotaki³  Maria Paravatou-Petsotas⁴  Spiros A. Vlahopoulos⁵ 

[1] Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635 Athens, Greece;Institute of Biosciences and Applications, NCSR ‘‘Demokritos”, 15310 Aghia Paraskevi, Greece;Institute of Nanoscience and Nanotechnology, NCSR ‘‘Demokritos”, 15310 Aghia Paraskevi, Greece;Institute of Nuclear and Radiological Sciences and Technology Energy and Safety, NCSR ‘‘Demokritos”, 15310 Aghia Paraskevi, Greece;Ηoremeio Research Laboratory, First Department of Paediatrics, National and Kapodistrian University of Athens, 11527 Athens, Greece;

关键词: drug delivery systems;    mitochondrial targeting;    drug combinations;    poly(ethyleneimine);    triphenylphosphonium cation;    old drugs;    chloroquine;    doxorubicin;   

DOI  :  10.3390/ph10040091

来源: DOAJ

【 摘 要 】

Drug delivery systems that target subcellular organelles and, in particular, mitochondria are considered to have great potential in treating disorders that are associated with mitochondrial dysfunction, including cancer or neurodegenerative diseases. To this end, a novel hyperbranched mitochondriotropic nanocarrier was developed for the efficient co-delivery of two different (both in chemical and pharmacological terms) bioactive compounds. The carrier is based on hyperbranched poly(ethyleneimine) functionalized with triphenylphosphonium groups that forms ~100 nm diameter nanoparticles in aqueous media and can encapsulate doxorubicin (DOX), a well-known anti-cancer drug, and chloroquine (CQ), a known chemosensitizer with arising potential in anticancer medication. The anticancer activity of this system against two aggressive DOX-resistant human prostate adenocarcinoma cell lines and in in vivo animal studies was assessed. The co-administration of encapsulated DOX and CQ leads to improved cell proliferation inhibition at extremely low DOX concentrations (0.25 μΜ). In vivo experiments against DU145 human prostate cancer cells grafted on immunodeficient mice resulted in tumor growth arrest during the three-week administration period and no pervasive side effects. The findings put forward the potential of such targeted low dose combination treatments as a therapeutic scheme with minimal adverse effects.

【 授权许可】

Unknown